Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus

Circulation
Michael DavidsonTheodore Mazzone

Abstract

Measurement of carotid intima-media thickness (CIMT) has been validated as a measure of atherosclerosis and as a predictor of future cardiovascular events. Compared with glimepiride, pioglitazone has been shown to slow the progression of atherosclerosis measured by CIMT in patients with type 2 diabetes mellitus. We evaluated individual cardiovascular risk factors as predictors of the change in CIMT produced by pioglitazone treatment by determining whether their addition to a baseline model resulted in loss of significance for the treatment effect on CIMT. Pioglitazone treatment led to improvement in levels of multiple cardiovascular risk markers, including high-sensitivity C-reactive protein, apolipoprotein B, apolipoprotein A1, high-density lipoprotein (HDL) cholesterol, triglyceride, insulin, and free fatty acid. At 24 weeks, there were significant differences in HDL cholesterol, triglyceride, total cholesterol, low-density lipoprotein cholesterol, insulin, body mass index, hip circumference, and high-sensitivity C-reactive protein between the pioglitazone and glimepiride treatment groups. After adjustment for 24-week on-treatment values of cardiovascular risk factors, only inclusion of the changes in HDL cholesterol and insu...Continue Reading

References

Dec 1, 1986·Journal of the American College of Cardiology·P L CannerW Friedewald
Feb 21, 1998·Annals of Internal Medicine·H N HodisS P Azen
Jun 27, 2000·Journal of Women's Health & Gender-based Medicine·S T YehE Barrett-Connor
Apr 13, 2001·JAMA : the Journal of the American Medical Association·S J RobinsUNKNOWN VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial
Nov 6, 2003·JAMA : the Journal of the American Medical Association·Olli T RaitakariJorma S A Viikari
Jun 16, 2005·Current Opinion in Cardiology·Theodore Mazzone
Sep 24, 2005·The New England Journal of Medicine·M Dominique Ashen, Roger S Blumenthal
Nov 15, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Philippe O SzaparyDaniel J Rader
Nov 15, 2006·JAMA : the Journal of the American Medical Association·Theodore MazzoneSteven M Haffner
Feb 8, 2007·JAMA : the Journal of the American Medical Association·Stephen J NichollsSteven E Nissen
Feb 17, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Giamila Fantuzzi, Theodore Mazzone
Mar 28, 2007·The New England Journal of Medicine·Steven E NissenUNKNOWN ILLUSTRATE Investigators
Apr 5, 2007·Current Medical Research and Opinion·John J P KasteleinUNKNOWN RADIANCE 1 and 2 Study Investigators
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Jul 17, 2007·Lancet·Theodore Mazzone
Sep 13, 2007·JAMA : the Journal of the American Medical Association·A Michael LincoffSteven E Nissen
Sep 28, 2007·The New England Journal of Medicine·Philip BarterUNKNOWN Treating to New Targets Investigators
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators

❮ Previous
Next ❯

Citations

Mar 17, 2010·Wiener medizinische Wochenschrift·Christoph H Saely, Heinz Drexel
Jul 20, 2011·Wiener medizinische Wochenschrift·Bernhard Föger
Jun 9, 2009·Current Atherosclerosis Reports·Catherine Fiévet, Bart Staels
Jul 16, 2010·Current Atherosclerosis Reports·Stephen J NichollsSteven E Nissen
Nov 26, 2010·Current Atherosclerosis Reports·Dan V MihailescuTheodore Mazzone
Feb 20, 2013·Journal of Agricultural and Food Chemistry·Linda GijsbersIvonne M C M Rietjens
Dec 23, 2008·Cardiovascular Research·Kwang Kon KohMichael J Quon
Oct 30, 2008·Current Opinion in Lipidology·D John Betteridge
Oct 6, 2010·Diabetes, Obesity & Metabolism·R A CantrellJ Sierra-Johnson
Oct 28, 2010·Diabetes, Obesity & Metabolism·G Schernthaner, R J Chilton
Jan 5, 2011·Diabetes, Obesity & Metabolism·B Charbonnel, B Cariou
Mar 31, 2012·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Mary L ModrickFrank M Faraci
Nov 24, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Aramesh SaremiPeter D Reaven
Oct 25, 2011·Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance·Ilias KylintireasRobin P Choudhury
Jun 12, 2012·Journal of Lipid Research·Janice V HuangGregory G Schwartz
Nov 11, 2011·The Journal of Clinical Endocrinology and Metabolism·Susan SamTheodore Mazzone
Sep 12, 2013·Vascular Health and Risk Management·Cong Zou, Honglin Hu
May 28, 2010·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Stephen J NichollsJean-Claude Tardif
May 28, 2010·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Matthew A CavenderA Michael Lincoff
Jan 12, 2012·Journal of Endocrinological Investigation·A AvogaroG Crepaldi
Sep 13, 2012·American Journal of Therapeutics·Nitin Verma, Vincent M Figueredo
Dec 4, 2009·QJM : Monthly Journal of the Association of Physicians·E Erdmann, R Wilcox
Jul 31, 2010·Expert Review of Cardiovascular Therapy·Pedro de Pablos-Velasco
Mar 31, 2012·Expert Review of Cardiovascular Therapy·Yu KataokaStephen J Nicholls
Dec 25, 2008·Expert Review of Cardiovascular Therapy·John M Galla, Stephen J Nicholls
Sep 25, 2012·Heart Failure Clinics·Jeong-a KimMichael J Quon
Apr 20, 2012·Trends in Endocrinology and Metabolism : TEM·Bertrand CariouBart Staels
Dec 5, 2009·The American Journal of Cardiology·Stephen J Nicholls
Jun 19, 2009·Medicina clínica·Carlos Lahoz, José M Mostaza
Jun 9, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·S Vigili de KreutzenbergA Avogaro
Mar 26, 2013·Diabetes, Obesity & Metabolism·A Consoli, G Formoso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.